HC Wainwright & Co. Downgrades TCR2 Therapeutics to Neutral

HC Wainwright & Co. analyst Robert Burns downgrades TCR2 Therapeutics (NASDAQ:TCRR) from Buy to Neutral.

HC Wainwright & Co. analyst Robert Burns downgrades TCR2 Therapeutics (NASDAQ:TCRR) from Buy to Neutral.

Total
0
Shares
Related Posts